Profile: Zymogenetics is a biopharmaceutical company with a development pipeline of proteins, antibodies, and antibody-like molecules. Our Recothrom® thrombin is used as topical hemostat to control moderate bleeding during surgical procedures. Our research and development organization combines broad expertise, capabilities and infrastructure in drug discovery, novel proteins, manufacturing & clinical development. We specialize in protein expression, process development and manufacturing scale-up in both mammalian and microbial systems. We focus our research efforts on inflammatory and autoimmune diseases. Our Recothrom® is indicated as an aid to hemostasis whenever oozing of blood and minor bleeding from capillaries and small venules is accessible, and control of bleeding by standard surgical techniques is ineffective or impractical.

The company was founded in 1981, has revenues of < USD 1 Million, has ~280 employees. NASDAQ:ZGEN (SEC Filings)